Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $63.40 Average PT from Brokerages

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $64.50.

Several equities research analysts recently weighed in on ELVN shares. Guggenheim started coverage on Enliven Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price objective on the stock. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. JonesTrading raised their price objective on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Finally, Stifel Nicolaus started coverage on Enliven Therapeutics in a research report on Tuesday, June 9th. They set a “buy” rating and a $60.00 target price for the company.

Insider Buying and Selling at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40. Following the completion of the transaction, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at $2,233,800. This trade represents a 10.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the transaction, the director directly owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ELVN. KBC Group NV bought a new position in Enliven Therapeutics during the 1st quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. raised its position in Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares during the last quarter. BNP Paribas Financial Markets raised its position in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Enliven Therapeutics during the 4th quarter worth $83,000. Finally, Quantbot Technologies LP raised its position in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after acquiring an additional 1,434 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Stock Down 0.2%

NASDAQ ELVN opened at $50.74 on Friday. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $52.39. The company has a market cap of $3.09 billion, a price-to-earnings ratio of -30.38 and a beta of 0.29. The business’s fifty day moving average is $42.34 and its 200 day moving average is $32.98.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. On average, research analysts anticipate that Enliven Therapeutics will post -1.71 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.